Morgan Stanley Reiterates Overweight Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)
Morgan Stanley reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report published on Friday,Benzinga reports. Morgan Stanley currently has a $183.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $175.00. JAZZ has been the topic of several other reports. HC Wainwright […]
Morgan Stanley reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report published on Friday,Benzinga reports. Morgan Stanley currently has a $183.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $175.00. JAZZ has been the topic of several other reports. HC Wainwright […]
